Healthcare

Cochlear develops implantable hearing solutions led by cochlear implants and bone conduction systems. Its global installed base, strong cash generation, and leadership in a growing medical niche make the company worth a closer look as it works through a tougher profit period.

Chemed combines hospice care through VITAS with the nationally known Roto-Rooter plumbing business. The appeal lies in recurring demand, strong profitability, and solid cash generation, with demographic support adding a long runway for the healthcare side.

CG Oncology is building around a late-stage bladder cancer therapy in an area with clear unmet need. The company has low debt, strong market attention, and a focused strategy, but its long-term profile depends on turning clinical progress into approval and commercial traction.

Amneal Pharmaceuticals is a generics-focused drugmaker that has been improving revenue, margins, and cash generation while expanding into more complex and specialty products. The business looks stronger operationally, making its evolution worth a closer look.

Alkermes is a specialty biopharma company built around neuroscience medicines, with LYBALVI emerging as its main engine. Revenue growth, positive free cash flow, and a possible oncology expansion have reshaped the company into a more focused and scalable business.

Belite Bio is a clinical-stage eye-disease biotech centered on tinlarebant, an oral treatment being developed for Stargardt disease and geographic atrophy. Its focused pipeline, low debt, and high-impact trial milestones make it an unusually visible name in retinal medicine.

BillionToOne develops blood-based diagnostic tests, with prenatal screening as its current engine and oncology as its next frontier. Revenue growth and improving profitability have been striking, making the company an increasingly important name in modern molecular testing.